|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
FDA (for specific uses)
|
|
gptkbp:ATCCode
|
L04AX02
|
|
gptkbp:CASNumber
|
50-35-1
|
|
gptkbp:category
|
orphan drugs
immunosuppressants
sedatives
glutarimides
phthalimides
teratogens
|
|
gptkbp:chemicalFormula
|
C13H10N2O4
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Chemie_Grünenthal
|
|
gptkbp:discoveredBy
|
gptkb:Heinrich_Mückter
|
|
gptkbp:eliminationHalfLife
|
5-7 hours
|
|
gptkbp:hasEnantiomer
|
gptkb:(R)-thalidomide
gptkb:(S)-thalidomide
|
|
gptkbp:introducedIn
|
1957
|
|
gptkbp:IUPACName
|
2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
|
|
gptkbp:legalStatus
|
prescription only
restricted distribution
|
|
gptkbp:mechanismOfAction
|
anti-inflammatory
anti-angiogenic
immunomodulatory
|
|
gptkbp:meltingPoint
|
270–272 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
258.23 g/mol
|
|
gptkbp:notableFor
|
gptkb:thalidomide_tragedy
causing birth defects in the 1950s and 1960s
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:PubChem_CID
|
CHEMBL651
5426
DB01041
|
|
gptkbp:relatedTo
|
gptkb:lenalidomide
gptkb:pomalidomide
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:peripheral_neuropathy
birth defects
constipation
rash
drowsiness
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
4Z8R6ORS6L
|
|
gptkbp:usedFor
|
gptkb:erythema_nodosum_leprosum
multiple myeloma
leprosy
HIV-associated wasting
|
|
gptkbp:withdrawn
|
many countries
|
|
gptkbp:bfsParent
|
gptkb:Celgene
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
thalidomide
|